Management
Repurposed drugs celecoxib and Fmoc-L-Leucine demonstrated antiglioma activity in comparative studies on cell lines, suggesting potential as alternatives or adjuncts in temozolomide-resistant glioblastoma multiforme cases [PMID:38542198].
Complications
In cases where patients cannot receive full radio-chemotherapy, survival drastically decreases, with median overall survival ranging from 10.6 to just 1.8 months, highlighting the critical importance of comprehensive treatment adherence [PMID:38542198].
Prognosis & Follow-up
With the current standard treatment regimen involving maximal safe surgical resection, radiotherapy (60 Gy over 30 sessions), and concomitant temozolomide administration followed by maintenance cycles, patients achieve a median overall survival of 16.1 months [PMID:38542198].
References
1 Uram Ł, Pieńkowska N, Misiorek M, Szymaszek Ż, Twardowska M, Siorek M et al.. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on . International journal of molecular sciences 2024. link
1 papers cited of 3 indexed.